Cannabis use among older adults: Potential risks and benefits to an aging population

项目摘要 美国老年人口正在急剧增加，从4800万增加到8800万，翻了一番 到2050年。随着越来越多的美国人长寿，面临的挑战是确保生活质量 随着生命质量的增加而维持。研究开始将重点放在理解这种变化上 人类正常衰老的生理基础，以及关于行为和药物策略的扩展 这可能有助于老年人最大限度地利用他们的晚年，最近的调查表明，一些人可能认为 合法化的大麻产品有一定的作用。与此同时，越来越多的合法化和 人们对大麻的接受速度很快。老年人是增长最快的大麻群体 美国的用户，在某些年龄段，他们的流行率上升了250%，他们认为使用几乎没有风险 每月吸食大麻(85.3%)，甚至每周吸食(79%)。全国性的调查还显示，老年人的 可能将大麻用于医疗目的而不是娱乐目的，以及使用大麻的常见原因 包括疼痛、焦虑、抑郁和失眠。有一些明显的和关键的问题表明，这种情况 摆姿势。首先，老年人的症状会得到缓解吗？这是否取决于他们的构成 他们正在使用的产品中的大麻类物质？第二，对神经认知和运动控制有影响吗？ 这可能是有害的，甚至可能是有益的，而做到这些也取决于大麻素的特征 使用的产品是什么？第三，我们如何帮助老年人作出有关大麻的决策？ 这项资助申请的首要目标是利用我们创新的流动药理实验室 方法和现有的老龄化研究基础设施，以更好地了解合法市场大麻的影响 60岁及以上的成年人。为此，拟议的研究将利用前瞻性的、以患者为中心的 观察性设计，招募和评估对使用大麻止痛感兴趣的老年人， 睡眠障碍，或负面影响和对大麻不感兴趣的对照组。 用户将选择和使用三种可食用大麻产品中的一种(即，CBD主导产品、 THC+CBD产品，或THC主导产品)，总共三个月。这项拟议的研究有三项 目标。首先，我们将探索不同成分的可食用大麻对希望 与使用大麻相比，使用大麻来治疗他们的疼痛、失眠或负面情绪(抑郁/焦虑) 非SING对照组采用患者总体印象改变量表进行评定。第二 我们将探讨食用不同成分的大麻对神经认知和运动控制的影响。 无论是在老年人中，还是随着时间的推移，这种情况都很严重。最后，我们将研究老年人 大麻使用者决定他们喜欢哪种类型的大麻产品。对这些目标的追求是巨大的

Project Summary The population of older adults in the U.S. is increasing dramatically, doubling from 48 million to 88 million by the year 2050. As more Americans live longer, the challenge is to assure that quality of life is being maintained along with quantity of life. Research is beginning to focus on understanding the changing physiology underlying normal human aging, as well as expand on behavioral and pharmacological strategies that may assist older adults to maximize their later years, and recent surveys suggest that some may believe that legalized cannabis products have a role to play. Simultaneously, the increasing legalization and acceptance of cannabis is occurring at a rapid pace. Older adults are the fastest growing group of cannabis users in the U.S., with prevalence up by 250% for in some age groups, who perceive virtually no risk of using cannabis monthly (85.3%) or even weekly (79%). National Surveys also showed that older adults were more likely to use cannabis for medicinal purposes than for recreational purposes, and common reasons for use include pain, anxiety, depression, and insomnia. There are obvious and critical questions that this situation poses. First, do older adults experience relief from their symptoms and does this depend on the constituent cannabinoids of the product they are using? Second, are there impacts on neurocognition and motor control that might be harmful, or even potentially beneficial, and do these, too, depend on the cannabinoid profile of the products being used? Third, how can we assist older adults in decision-making regarding cannabis? The overarching goal of this grant application is to leverage our innovative mobile pharmacology laboratory approach and existing aging research infrastructure to better understand the effects of legal market cannabis in adults aged 60 and over. To that end, the proposed research will utilize a prospective, patient-centered observational design to recruit and assess older adults who are interested in using cannabis for pain, trouble sleeping, or negative affect and a comparison group who are not interested in cannabis use. Users will choose and use one of three types of edible cannabis products (i.e., a CBD dominant product, a THC+CBD product, or a THC dominant product) for a total of three months. The proposed research has three aims. First, we will explore the effects of edible cannabis of varying composition among older adults who desire to use cannabis to treat their pain, trouble sleeping, or negative affect (depression/anxiety) as compared to a non-sing comparison group assessed by changes in the Patient Global Impression of Change scale. Second we will explore the effects of edible cannabis use of varying composition on neurocognition and motor control both acutely and over time among older adults. Finally, we will examine the process by which older adult cannabis users decide what type of cannabis product they prefer. Pursuit of these aims has tremendous